ArticleCancer research2021
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Open access · hybridAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Nucleic sexual hormone receptor signaling pathways in breast cancer: function regulation, crosstalk, and therapeutic implications.NPJ precision oncology · 2026Review
- Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside.Breast cancer research : BCR · 2026Review
- ESR1 fusion proteins in breast cancer: distinguishing oncogenic drivers from passenger events.Oncogene · 2026Review
- Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells.Cancer research communications · 2026Article
- ESR1 fusions in breast cancer: functions, mechanisms and therapeutic opportunities.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- NF1-depleted ERScience translational medicine · 2025Article
- Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.Molecular oncology · 2025Review
- PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.Molecular cancer therapeutics · 2024Article
- ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Endocrinology · 2024Article
- Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Endocrinology · 2024Review
- Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer.Breast cancer research : BCR · 2024Article
- Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Cancer research · 2023Article
- RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.Cancer research · 2023Article
- High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.Cell reports · 2023Article
- Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.Nature communications · 2023Article
- Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.Cancer research communications · 2023Article
- Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.The oncologist · 2023Article
- ESR1 fusions and therapeutic resistance in metastatic breast cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 4 countries.
Xuxu GouLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-2318-778X
Meenakshi AnuragLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Jonathan T LeiLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Beom-Jun KimLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Purba SinghLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Sinem SekerLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Diana FandinoLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Airi HanLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Saif RehmanQueens' College, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7270-1752
Jianhong HuHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
Viktoriya KorchinaHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-9069-8806
Harshavardhan DoddapaneniHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
Lacey E DobroleckiLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-6839-629X
Nicholas MitsiadesDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-4659-476X
Michael T LewisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Alana L WelmDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Shunqiang LiDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri.
Adrian V LeeDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-9917-514X
Dan R RobinsonMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-2337-7439
Charles E FouldsLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-4908-1473
Matthew J EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. mjellis@bcm.edu.ORCID 0000-0002-8467-8534
Baylor College of Medicine · USHuntsman Cancer Institute · USMagee-Womens Research Institute · USUniversity of Cambridge · GBUniversity of Michigan · USWashington University in St. Louis · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MATTHEW J ELLIS · 2014 to 2026
$24.5MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5MTHE RNA HELICASE EIF4A IS A THERAPEUTIC VULNERABILITY IN TRIPLE-NEGATIVE BREAST CANCERU54CA233223 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MITSIADES, NICHOLAS · 2018 to 2022
$7.0MTraining Program in Translational Biology and Molecular MedicineT32GM088129 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ROONEY, CLIONA M., VAN DEN VEYVER, IGNATIA B · 2010 to 2019
$3.0MTranslational Breast Cancer Research Training ProgramT32CA203690 · NCI · BAYLOR COLLEGE OF MEDICINE · PI FUQUA, SUZANNE AW, RIMAWI, MOTHAFFAR FAHED · 2018 to 2022
$1.0MHigh Throughput Genomic Sequencer at BCM Core FacilityS10OD023469 · OD · BAYLOR COLLEGE OF MEDICINE · PI CHEN, RUI · 2017 to 2017
$600kNCI NIH HHS P30 CA125123NCI NIH HHS P50 CA186784NCI NIH HHS T32 CA203690NCI NIH HHS U54 CA224076NCI NIH HHS U54 CA233223NIGMS NIH HHS T32 GM088129NIH HHS S10 OD023469
Abstract
Genomic analysis has recently identified multiple
Indexed as
Drug Resistance, NeoplasmMutationAnimalsAntineoplastic Agents, HormonalApoptosisBiomarkers, TumorBreast NeoplasmsCell ProliferationEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudeOncogene Proteins, FusionPrognosisAntineoplastic Agents, HormonalBiomarkers, TumorESR1 protein, humanEstrogen Receptor alphaOncogene Proteins, Fusion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.